Erratum: Psychotropic drug use among preschool children in the Medicaid program from 36 states (Am J Public Health (2015) 105, 3 (524-529) DOI: 10.2105/AJPH.2014.302258);Psychotropic drug use among preschool children in the medicaid program from 36 states

American Journal of Public Health

Volumn 105, Issue 3, 2015, Pages 524-529

  Garfield, Lauren D ^a,c   Brown, Derek S ^a   Allaire, Benjamin T ^b   Ross, Raven E ^a   Nicol, Ginger E ^a   Raghavan, Ramesh ^a  

^a WASHINGTON UNIVERSITY   (United States)

^b RTI INTERNATIONAL   (United States)

^c Mercy Health Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PSYCHOTROPIC AGENT;

AGE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BIPOLAR DISORDER; BRAIN; DEPRESSIVE DISORDER; DRUG EFFECTS; DRUG UTILIZATION; FEMALE; GROWTH, DEVELOPMENT AND AGING; HUMAN; INFANT; INSURANCE; MALE; MEDICAID; OFF LABEL DRUG USE; PRESCHOOL CHILD; PRESCRIPTION DRUG DIVERSION; PSYCHOTIC DISORDERS; STANDARDS; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TRENDS; UNITED STATES;

AGE FACTORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BIPOLAR DISORDER; BRAIN; CHILD, PRESCHOOL; DEPRESSIVE DISORDER; DRUG UTILIZATION; FEMALE; HUMANS; INFANT; INSURANCE CLAIM REVIEW; LOGISTIC MODELS; MALE; MEDICAID; OFF-LABEL USE; PRESCRIPTION DRUG DIVERSION; PSYCHOTIC DISORDERS; PSYCHOTROPIC DRUGS; UNITED STATES;

EID: 84922693078     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2014.302258e     Document Type: Erratum

References (35)

1. Zito JM, Safer DJ, Valluri S, Gardner JF, Korelitz JJ, Mattison DR. Psychotherapeutic medication prevalence in Medicaid-insured preschoolers. J Child Adolesc Psy-chopharmacol. 2007;17(2):195-203.
2. Olfson M, Crystal S, Huang C, Gerhard T. Trends in antipsychotic drug use by very young, privately insured children. J Am Acad Child Adolesc Psychiatry. 2010; 49(1):13-23.
3. Chirdkiatgumchai V, Xiao H, Fredstrom BK, et al. National trends in psychotropic medication use in young children: 1994-2009. Pediatrics. 2013;132(4):615-623.
4. Zito JM, Safer DJ, Gardner JF, Boles M, Lynch F. Trends in the prescribing of psychotropic medications to preschoolers. JAMA. 2000;283(8):1025-1030.
5. Olfson M, Blanco C, Wang S, Laje G, Correll CU. National trends in the mental health care of children, adolescents, and adults by office-based physicians. JAMA Psychiatry. 2014;71(1):81-90.
6. Constantine RJ, Jentz S, Bengtson M, McPherson M, Andel R, Jones MB. Exposure to antipsychotic medications over a 4-year period among children who initiated antipsychotic treatment before their sixth birthday. Pharmacoepidemiol Drug Saf. 2012;21(2):152-160.
7. Williams PG, Woods C, Stevenson M, Davis DW, Radmacher P, Smith M. Psychotropic medication use in children with autism in the Kentucky Medicaid population. Clin Pediatr (Phila). 2012;51(10):923-927.
8. Luby JL, Stalets MM, Belden AC. Psychotropic prescriptions in a sample including both healthy and mood and disruptive disordered preschoolers: relationships to diagnosis, impairment, prescriber type, and assessment methods. J Child Adolesc Psychopharmacol. 2007;17(2):205-215.
9. Ferguson DG, Glesener DC, Raschick M. Psycho-tropic drug use with European American and American Indian children in foster care. J Child Adolesc Psycho-pharmacol. 2006;16(4):474-481.
10. Martin A, Van Hoof T, Stubbe D, Sherwin T, Scahill L. Multiple psychotropic pharmacotherapy among child and adolescent enrollees in Connecticut Medicaid managed care. Psychiatr Serv. 2003;54(1):72-77.
11. dosReis S, Zito JM, Safer DJ, Gardner JF, Puccia KB, Owens PL. Multiple psychotropic medication use for youths: a two-state comparison. J Child Adolesc Psycho-pharmacol. 2005;15(1):68-77.
12. Patel NC. Antipsychotic use in children and adolescents from 1996 to 2001: epidemiology, prescribing practices, and relationships with service utilization. Ann Arbor, MI: ProQuest Information and Learning; 2005.
13. Morrato EH, Druss B, Hartung DM, et al. Small area variation and geographic and patient-specific determinants of metabolic testing in antipsychotic users. Phar-macoepidemiol Drug Saf. 2011;20(1):66-75.
14. Leslie LK, Raghavan R, Hurley M, Zhang J, Landsverk J, Aarons G. Investigating geographic variation in use of psychotropic medications among youth in child welfare. Child Abuse Negl. 2011;35(5):333-342.
15. Matone M, Localio R, Huang Y, dosReis S, Feudtner C, Rubin D. The relationship between mental health diagnosis and treatment with second-generation antipsy-chotics over time: a national study of U.S. Medicaid-enrolled children. Health Serv Res. 2012;47(5):1836-1860.
16. Medicaid Medical Directors Learning Network, Rutgers Center for Education and Research on Mental Health Therapeutics. Antipsychotic medication use in Medicaid children and adolescents: report and resource guide from a 16-state study. 2010. Available at: http://rci.rutgers.edu/;cseap/MMDLNAPKIDS.html. Accessed October 1, 2014.
17. Coyle JT. Psychotropic drug use in very young children. JAMA. 2000;283(8):1059-1060.
18. Zito JM, Derivan AT, Kratochvil CJ, Safer DJ, Fegert JM, Greenhill LL. Child and adolescent psychiatry and mental health. Child Adolesc Psychiatry Ment Health. 2008;2(1):24.
19. Safer DJ, Zito JM. Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: children versus adolescents. J Child Adolesc Psychopharmacol. 2006;16(1-2):159-169.
20. Safer DJ. A comparison of risperidone-induced weight gain across the age span. J Clin Psychopharmacol. 2004;24(4):429-436.
21. Wigal SB, Gupta S, Greenhill L, et al. Pharmacoki-netics of methylphenidate in preschoolers with attention-deficit/hyperactivity disorder. J Child Adolesc Psycho-pharmacol. 2007;17(2):153-164.
22. Fanton J, Gleason MM. Psychopharmacology and preschoolers: a critical review of current conditions. Child Adolesc Psychiatr Clin N Am. 2009;18(3):753-771.
23. Cunningham SA, Kramer MR, Narayan KM. Incidence of childhood obesity in the United States. N Engl J Med. 2014;370(5):403-411.
24. Vieweg WV, Kuhnley LJ, Kuhnley EJ, et al. Body mass index (BMI) in newly admitted child and adolescent psychiatric inpatients. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(4):511-515.
25. Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2006;45(7):771-791.
26. Biederman J, Mick E, Wozniak J, Aleardi M, Spencer T, Faraone SV. An open-label trial of risperidone in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol. 2005;15(2):311-317.
27. Bobo WV, Cooper WO, Stein CM, et al. Antipsy-chotics and the risk of type 2 diabetes mellitus in children and youth. JAMA Psychiatry. 2013;70(10):1067-1075.
28. Raghavan R, Brown DS, Thompson H, Ettner SL, Clements LM, Key W. Medicaid expenditures on psy-chotropic medications for children in the child welfare system. J Child Adolesc Psychopharmacol. 2012;22 (3):182-189.
29. Raghavan R, Brown DS, Allaire BT, Garfield LD, Ross RE. Medicaid expenditures on psychotropic medications for maltreated children: a study of 36 states. Psychiatr Serv. 2014;65(12):1445-1451.
30. Gilmer T, Kronick R, Fishman P, Ganiats TG. The Medicaid Rx model: pharmacy-based risk adjustment for public programs. Med Care. 2001;39(11):1188-1202.
31. Thompson Reuters: Red Book 2011. Available at: http://www.redbook.com. Accessed September 21, 2011.
32. International Classification of Diseases, Ninth Revision, Clinical Modification. Hyattsville, MD: National Center for Health Statistics; 1980. DHHS publication PHS 80-1260.
33. Zito JM, Burcu M, Ibe A, Safer DJ, Magder LS. Antipsychotic use by Medicaid-insured youths: impact of eligibility and psychiatric diagnosis across a decade. Psychiatr Serv. 2013;64(3):223-229.
34. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients. Med Care. 2008;46(11):1125-1133.
35. Zito JM, Safer DJ, de Jong-van den Berg LT, et al. A three-country comparison of psychotropic medication prevalence in youth. Child Adolesc Psychiatry Ment Health. 2008;2(1):26.